Skip to main content
Signal8
Launch Terminal

PepGen Inc. (PEPG)

PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in Boston, Massachusetts.

Sector: Pharmaceutical Preparations

Industry: Biotechnology

PepGen Inc. logo

PepGen Inc.

NASDAQ:PEPGHealthcare
-2.07%$2.36
AH$2.41+2.12%vs close
Mkt Cap$163.45M
Float49.09M
O/S69.26M
Vol
$ Vol
RVOL
Inst Own75.2%
SI7.8%
Earnings
Dilution
PepGen Inc. logoNASDAQ:PEPG$2.36-2.07%
Phase Distribution
5 lead-sponsored trials·2 active·1 completed
Phase 11
Phase 24
Status Overview
Recruiting2
Completed1
Stopped2

Trials need funding. See this company's dilution risk and cash position.

Clinical Trials
Status
Phase
  • Phase 2
    Terminated

    A Study Of PGN-EDO51 In Participants With Duchenne Muscular Dystrophy Amenable To Exon 51-Skipping Treatment

    PGN-EDO51

    Duchenne Muscular Dystrophy

    Enrollment
    7
    Start
    Jan 2024
    Primary Completion
    Aug 2025
    Completion
    Aug 2025
    NCT06079736
  • Phase 2
    Recruiting

    A Clinical Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1

    PGN-EDODM1

    Myotonic Dystrophy 1

    Enrollment
    24
    Start
    Dec 2024
    Primary Completion
    Mar 2027est.
    Completion
    Mar 2027est.
    NCT06667453
  • Phase 2
    Withdrawn

    A Study of PGN-EDO51 or Placebo in People With Duchenne Muscular Dystrophy Amenable to Exon 51-Skipping Treatment

    IV infusion

    Duchenne Muscular Dystrophy (DMD)

    Enrollment
    0
    Start
    Dec 2024
    Primary Completion
    May 2025
    Completion
    May 2025
    NCT06833931
  • Phase 2
    Recruiting

    An Open-Label Extension Study of PGN-EDODM1 in People With Myotonic Dystrophy Type 1 (FREEDOM-OLE)

    PGN-EDODM1

    Myotonic Dystrophy 1

    Enrollment
    48
    Start
    Dec 2025
    Primary Completion
    Jan 2029est.
    Completion
    Jan 2029est.
    NCT07220603
  • Phase 1
    Completed

    Safety, Tolerability, PK, and PD Study of PGN-EDODM1 in Participants With Myotonic Dystrophy Type 1

    PGN-EDODM1 for infusion

    Myotonic Dystrophy 1

    Enrollment
    24
    Start
    Dec 2023
    Primary Completion
    Oct 2025
    Completion
    Oct 2025
    NCT06204809
Search ClinicalTrials.gov for “PepGen”